The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions. The solution is free of unconjugated APC and unconjugated antibody.
CD158B2 antibody, CD158b antibody, GL183 antibody, KIR-023GB antibody, KIR-K7b antibody, KIR-K7c antibody, KIRCL23 antibody, NKAT antibody, NKAT2 antibody, NKAT2A antibody, NKAT2B antibody, p58 antibody, killer cell immunoglobulin like receptor, two Ig domains and long cytoplasmic tail 3 antibody, KIR2DL3 antibody
Background
CD158b is expressed on natural killer cells and a subset of T cells. It is a member of the immunoglobulin superfamily containing two immunoglobulin C2-type domains. Both variants and alternative isoforms of CD158b have been reported. The interaction of CD158b with specific HLA-C antigens on a target cell (HLA-Cw1, HLA-Cw3, HLA-Cw7 alleles, for example) inhibits cytotoxicity and prevents target cell lysis and death. The interactions between KIR and MHC class I are thought to be important in NK cell and T cell regulation following antigen stimulation. The absence of ligands for KIRs may lower the threshold for activation through activating receptors and increase inflammation and susceptibility to autoimmune disease.